Drug and Therapy Development for Triple Negative Breast Cancer

Product Details

• Publisher: Wiley; June 7, 2023
• Language: English
• ISBN: 9783527351756
• ISBN: 9783527841189

Introduction

Triple Negative Breast Cancer (TNBC) is a challenging form of breast cancer that lacks the most common biomarkers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/neu) amplification. It accounts for approximately 15-20% of all breast cancer cases and is associated with a poorer prognosis compared to other types of breast cancer.

In recent years, there has been significant progress in the field of TNBC research and treatment. The book Drug and Therapy Development for Triple Negative Breast Cancer by Pravin Kendrekar provides a comprehensive compilation of modern diagnostic and treatment methods for TNBC. The book covers various aspects of TNBC, including its molecular causes, detection, diagnostic tools, treatment procedures, pharmacology, and new and experimental therapies.

Review

Drug and Therapy Development for Triple Negative Breast Cancer is a highly informative and authoritative resource for healthcare professionals, researchers, and students interested in breast cancer. The book is edited by a team of distinguished practitioners who have extensive experience in the field of TNBC. Each chapter is written by experts in the respective fields, ensuring that the information provided is up-to-date and based on the latest research.

One of the strengths of this book is its comprehensive coverage of various aspects of TNBC treatment. The book starts with a thorough introduction to TNBC and HER receptors in breast cancers. It then explores the etiology and therapy of hormone receptor-positive breast cancer and the early-stage diagnosis of breast cancer. The book also delves into the application of artificial intelligence to breast cancer diagnosis, providing valuable insights into the potential of technology in improving early detection and accurate diagnosis.

In addition to the conventional treatment methods, the book also discusses new and experimental therapies for TNBC, including nanotherapeutics and photothermal therapies. These emerging therapies have shown promising results in preclinical and early clinical trials, and their inclusion in this book makes it a valuable resource for researchers and clinicians interested in advancing the field of TNBC treatment.

Another highlight of this book is its focus on future treatment approaches, including machine learning methods for earlier detection and more accurate diagnosis. This demonstrates the book’s commitment to staying at the forefront of advancements in TNBC research and treatment. The book provides insights into the role of DNA replication stress and genome instability in breast cancer, offering a deeper understanding of the underlying mechanisms of TNBC and potential targets for future therapies.

Order Now and Make a Difference

If you are a medicinal or pharmaceutical chemist, oncologist, or a professional working in the pharmaceutical industry or hospital settings, Drug and Therapy Development for Triple Negative Breast Cancer is a must-read. The comprehensive information and insights provided in this book will enhance your knowledge and understanding of TNBC and contribute to advancements in its diagnosis and treatment.

By ordering this book, you are not only gaining access to a valuable resource but also supporting the ongoing research and development efforts in the field of TNBC. Your purchase will contribute to the dissemination of knowledge and the advancement of medical science, ultimately helping patients with TNBC receive better care and improve their outcomes.

Don’t miss out on this opportunity to expand your knowledge and make a difference in the lives of those affected by TNBC. Order your copy of Drug and Therapy Development for Triple Negative Breast Cancer today and join the movement towards a brighter future for TNBC patients.